NV-ALVARIA.
13.9.2022 15:01:49 CEST | Business Wire | Press release
Today, Alvaria, Inc. is pleased to announce the successful deployment of Alvaria Cloud™ in Google Cloud Platform (GCP). Adding GCP to their current offerings of AWS and Azure expands the available public cloud options Alvaria provides to support customer experience (CX) and employee engagement (EX) strategies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005584/en/
Alvaria CEO, Jeff Cotten rehearses "The Modern Contact Center" for opening day at ACE 2022 where he unveils a new engagement framework, The Alvaria Enterprise Modernization Journey (Photo: Business Wire)
Providing multiple public cloud selections, including GCP, is a part of the commitment Alvaria has made to provide choice for customers in order to meet their business objectives with the proper products and services. As an enterprise CCaaS vendor, Alvaria now provides industry leading support to help enterprise brands with complex and specific configuration requirements evolved to meet the needs of rapidly evolving customer expectations.
ACE 2022, Alvaria U kicks off at 9:00 AM PDT with The Modern Contact Center, an address from Chief Executive Officer, Jeff Cotten. He will unveil a new engagement framework, The Alvaria Enterprise Modernization Journey.
“We will assist customers through a process of determining business and technology objectives, with a goal of understanding where they are today and the desired end state,” said Jeff Cotten. “We will then map the best fit of products and services that align to their business goals because with Alvaria you are not going to hear and see a one-size-fits-all approach. We aim to enable choice and flexibility.”
In addition to the CEO Address, Alvaria has a full agenda planned for former Aspect Software, Noble Systems and Alvaria customers and partners including new product demonstrations, insights from industry experts, as well as product tips and tricks and a special keynote, Customer Obsession: How to Satisfy Inherently Unsatisfiable Customers, by Gibson Biddle, Entrepreneur, Advisor, Former Netflix VP Product Management.
Core to the success of ACE each year is the participation of Alvaria Partners. Alvaria would like to thank a select group of partners who have sponsored the event: Call Design, Communik.me, CS Infocomm, ITFor, Resolutte, Rich Communication Technology, Rising Interactions and Waterfield Technologies. Furthermore, this year, Alvaria introduced the ACE Partner Certified Seller track, designed to enable Alvaria partners worldwide with tools to win business.
Alvaria SVP of Global Marketing, Colleen Sheley said, “The pandemic has greatly emphasized the need for enterprises to be resilient, secure and continue to deliver exceptional customer experiences. Brands want to invest in accelerating their consumer technology initiatives and now with the deployment of Alvaria Cloud in GCP there's now less friction and more choice than ever before.”
Registration for the virtual event is still open. Get complimentary access with code: VIRTUAL-ACE22-BEMYGUEST
To register, please visit www.alvaria.com/ace
Alvaria was founded through the merger of Aspect Software and Noble Systems. We are the world leader in enterprise-scale customer experience (CX) and workforce engagement management (WEM) solutions. Our name is derived from Latin for “hives” – nature’s perfect form for millions of years – bringing you solutions that are scalable, resilient and secure, with efficiency, speed and pinpoint accuracy. ALVARIA™. Reshaping Customer Experience™. For more information, please visit www.alvaria.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005584/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom